Jo Howard talks to us at EHA 2019 about results from the randomized placebo-controlled phase 3 HOPE trial of voxelotor in adults and adolescents with sickle cell disease.
Questions
1. What are the limitations of the current standard of care for sickle cell disease? (0:05)
2. What is the mechanism of action of voxelotor? (1:00)
3. Could you tell us a little about the HOPE study and its efficacy findings? (1:52)
4. What is the safety and tolerability of voxelotor? (3:55)
5. What will be the next steps in the clinical development of voxelotor? (5:16)
Jo Howard is on the advisory board and a consultant for Global Blood Therapeutics and Imara. She is also on the Speaker’s Bureau for Novartis, Terumo and Medica.
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
